Astellas to accelerate ocular disease treatments with $5.9 billion acquisition
European Pharmaceutical Review
MAY 2, 2023
billion in 2028, according to GlobalData’s Pharma Intelligence Center. Limiting progression of geographic atrophy via C5 inhibition Specifically, ACP, a complement C5 inhibitor, is an investigational drug for GA secondary to AMD and has significant potential to deliver value to a large and underserved patient base, according to Astellas.
Let's personalize your content